Baishideng Publishing Group Co., Limited
Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report
Name of Journal: World Journal of Translational Medicine
ESPS Manuscript NO: 4817
Title: Peptide-based boronates: How to achieve tissue specificity in anticancer therapy
Reviewer code: 00530994
Science editor: Song, Xiu-Xia
Date sent for review: 2013-07-25 15:30
Date reviewed: 2013-08-02 17:27

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
[ ] Grade A (Excellent)	[Y] Grade A: Priority Publishing	Google Search:	[ ] Accept
[ ] Grade B (Very good)	[ ] Grade B: minor language polishing	[ ] Existed	[ ] High priority for publication
[Y] Grade C (Good)	[ ] Grade C: a great deal of language polishing	[ ] No records	
[ ] Grade D (Fair)		BPG Search:	[ ]Rejection
[ ] Grade E (Poor)	[ ] Grade D: rejected	[ ] Existed	[ ] Minor revision
		[ ] No records	[Y] Major revision

COMMENTS TO AUTHORS
Although the article is well-written, it is noting more than an appraisal of another article (reference 14). In order to qualify as a review a well-balanced appraisal of the literature is essential.

Baishideng Publishing Group Co., Limited
Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report
Name of Journal: World Journal of Translational Medicine
ESPS Manuscript NO: 4817
Title: Peptide-based boronates: How to achieve tissue specificity in anticancer therapy
Reviewer code: 00065149
Science editor: Song, Xiu-Xia
Date sent for review: 2013-07-25 15:30
Date reviewed: 2013-08-02 20:06

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
[ ] Grade A (Excellent)	[ ] Grade A: Priority Publishing	Google Search:	[ ] Accept
[Y] Grade B (Very good)	[Y] Grade B: minor language polishing	[ ] Existed	[ ] High priority for publication
[ ] Grade C (Good)	[ ] Grade C: a great deal of language polishing	[ ] No records	
[ ] Grade D (Fair)		BPG Search:	[ ]Rejection
[ ] Grade E (Poor)	[ ] Grade D: rejected	[ ] Existed	[Y] Minor revision
		[ ] No records	[ ] Major revision

COMMENTS TO AUTHORS

This is a well written editorial. I have only a few questions/suggestions as listed below. (i) Page 3, line 11, it should be read as "In fact"; (ii) Page 3, "bortezomib presents some shortcomings as a therapeutic agent"; the shortcomings should include "development of tumour resistance to brotezomib". (iii) The author mentioned in several times about "tumour-specific protease". Is it true that such a protease is completely not present in normal cells/tissues or it exists in normal cells in a lower level? The author needs to further clarify this point. (iv) One more point: tumour cellular pH is more acidic than a normal cell, which might favour the pH-dependent equilibrium of "pro-soft" drugs to gain the activity selectively in tumour cells. The author needs to discuss this point. (v) The administration route of the drug in figure 3 should be mentioned.